Static Chart Oncternal Therapeutics, Inc.

Equities

Delayed Nasdaq Other stock markets 11:55:05 2024-06-20 EDT			5-day change	1st Jan Change
8.152 ^USD	+1.90%		-1.78%	-23.98%

05-30	Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
05-09	Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Duration

Period